The global nuclear medicine isotopes market is estimated to grow at a significant CAGR during the forecast period. Nuclear medicine is used to diagnose and test the effect of a wide range of diseases, including heart diseases, tumors, gastrointestinal, neurological disorders, and endocrine disorders, as well as other abnormalities in the body.
Nuclear medicine isotopes can be used to treat a variety of medical diseases, including cancer, by weakening or destroying certain targeted cells. Positron emission tomography (PET) is a precise method that uses isotopes created in a cyclotron. With fluorine-18 as the tracer, it is widely used in oncology and has been proved to be the most accurate non-invasive technique for detecting and evaluating most cancers. Targeted alpha therapy (TAT) or alpha radio-immunotherapy is an emerging field in cancer treatment, particularly for the control of dispersed tumors. Nuclear medicine is beneficial in oncology in a variety of functions across the course of the disease. Some new approvals of isotopes have been witnessed. For instance, in January 2021, the United States Food and Drug Administration (US FDA) has approved NorthStar Medical Radioisotopes, LLC's production of Mo-99 from concentrated Mo-98 (CMO-98) and relevant software upgrades for the RadioGenix System (technetium Tc 99m generator).
Market Coverage
o By Type
o By Application
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Nuclear Medicine Isotopes Market Segmentation
o Stable Isotopes
o Radio Isotopes
o Nuclear Therapy
o Equipment Radioactive Source
o Diagnosis
Global Nuclear Medicine Isotopes Market is Segmented by Region
North America
Europe
Asia-Pacific
Rest of the World
REQUEST FOR TABLE
OF CONTENT